Product nameAnti-PRAK/MK5 antibody
See all PRAK/MK5 primary antibodies
DescriptionRabbit polyclonal to PRAK/MK5
Tested applicationsSuitable for: WB, ICC/IFmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat, Pig
Recombinant fragment corresponding to Human PRAK/MK5 aa 197-467. (AAH47284)
- WB: 293T and H1299 whole cell lysates; A431, HeLaS3, HepG2, MOLT4 and Raji cell lines ICC/IF: HeLa cells
This product was previously labelled as PRAK
Storage instructionsShipped at 4°C. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.00
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 1.21% Tris, 0.75% Glycine, 20% Glycerol
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab97332 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/3000. Predicted molecular weight: 54 kDa.|
|ICC/IF||1/100 - 1/200.|
FunctionMediates stress-induced small heat shock protein 27 phosphorylation.
Tissue specificityExpressed ubiquitously.
Sequence similaritiesBelongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family.
Contains 1 protein kinase domain.
modificationsPhosphorylated on Thr-182; which is the regulatory phosphorylation site and is located on the T-loop/loop 12.
Cellular localizationCytoplasm. Nucleus. Also observed in the nucleus.
- Information by UniProt
- MAP kinase-activated protein kinase 5 antibody
- MAPK-activated protein kinase 5 antibody
- MAPK5_HUMAN antibody
All lanes : Anti-PRAK/MK5 antibody (ab97332) at 1/500 dilution
Lane 1 : 293T whole cell lysate
Lane 2 : H1299 whole cell lysate
Lysates/proteins at 30 µg per lane.
Predicted band size: 54 kDa
ab97332, at a 1/200 dilution, staining PRAK/MK5 in paraformaldehyde fixed HeLa cells by Immunofluorescence.
Lower image is merged with DNA probe.
ab97332 has not yet been referenced specifically in any publications.